SR 144528;5-(4-Chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-1H-pyrazole-3-carboxamide;1H-Pyrazole-3-carboxamide, 5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-;SR-144528,SR144528;5-(4-Chloro-3-methylphenyl)-1-(4-methylbenzyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl)-1H-pyrazole-3-carboxamide;5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl]-1H-pyrazole-3-carboxamide;SR144528, 10 mM in DMSO
SR144528 is a potent and selective CB2 receptor antagonist used in research to study cannabinoid receptor signaling; it modulates forskolin-sensitive adenylyl cyclase activity in CHO-CB2 cells; reduces caspase-3 activity in Raw264.7 macrophages; inhibits microsomal acyl-coenzyme A:cholesterol acyltransferase (ACAT) activity; and enhances delayed gastric emptying without affecting gastrointestinal motility when administered alone.